Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL

Both CAR-Ts Offer Survival Gains, With Longer Data For Kite’s Product

Data at ASH show CAR-T therapies may replace standard of care in an earlier line of large B-cell lymphoma with similar response rates and event-free survival for Kite’s established Yescarta and Bristol’s newer Breyanzi.

Game changer as a business creative metaphor art
After years with chemo and stem cell transplant as the only second-line option, CAR-T therapy offers a more effective solution • Source: Alamy

Phase III clinical trial results presented on 11 and 12 December at the American Society of Hematology (ASH) annual meeting for two CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapies – Bristol Myers Squibb Company’s Breyanzi (lisocabtagene maraleucel) and Gilead Sciences, Inc. subsidiary Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel) – are being hailed as practice-changing for adults with large B-cell lymphoma (LBCL) who were refractory or relapsed within 12 months of first-line treatment.

Each of the CAR-T products, both of which are approved after two or more prior lines of treatment, quadrupled event-free...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More from R&D

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.